• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

奥希替尼治疗一名具有胚系EGFR T790M、体细胞EGFR 19-缺失、TP53和PIK3CA突变的肺腺癌患者的益处。

Benefits of osimertinib treat a lung adenocarcinoma patient with germline EGFR T790M, somatic EGFR 19-Del, TP53 and PIK3CA mutations.

作者信息

Li Yingxue, Li Guangqi, Zheng Zheng, Wen Wenjuan, Zhao Haihui, Liu Xia, Xie Jiaping, Han Lin

机构信息

Department of Pathology, Liaocheng People's Hospital, Liaocheng, 252000, Shandong, People's Republic of China.

Department of Pathology, School of Basic Medicine Science, Shandong University, Jinan, 250012, Shandong, People's Republic of China.

出版信息

Hered Cancer Clin Pract. 2024 Aug 19;22(1):13. doi: 10.1186/s13053-024-00286-4.

DOI:10.1186/s13053-024-00286-4
PMID:39160638
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11331667/
Abstract

BACKGROUND

Somatic mutations in the EGFR gene occur in about 50% of non-small cell lung cancers, with the T790M mutation significantly contributing to secondary resistance against EGFR-TKI drugs. However, EGFR T790M germline mutations rarely occur.

CASE PRESENTATION

In this study, we report a case of a lung adenocarcinoma family lineage linked to a germline EGFR T790M mutation. The main subject was diagnosed with stage IV lung adenocarcinoma and experienced a 19-month period without disease progression while treated with Osimertinib. We collected both clinicopathological and familial data from a patient with lung adenocarcinoma. Next-generation sequencing of 40 key genes was performed on the proband's tumor tissue. To detect EGFR germline mutations, Sanger sequencing was conducted on peripheral blood mononuclear cells from the proband and his two daughters. Mutations such as EGFR T790M, EGFR 19-Del, TP53, and PIK3CA were identified in the proband's lung cancer tissue. Additionally, germline EGFR T790M mutations were confirmed in the proband and his daughters through sequencing of their peripheral blood samples. CT scans revealed multiple pulmonary nodules in both daughters.

CONCLUSIONS

These observations suggest that germline mutations in EGFR T790M could be strongly linked to a familial predisposition to lung cancer.

摘要

背景

表皮生长因子受体(EGFR)基因的体细胞突变约发生于50%的非小细胞肺癌中,其中T790M突变是导致对EGFR酪氨酸激酶抑制剂(EGFR-TKI)药物产生继发性耐药的重要原因。然而,EGFR T790M种系突变很少发生。

病例报告

在本研究中,我们报告了一例与种系EGFR T790M突变相关的肺腺癌家族谱系病例。主要患者被诊断为IV期肺腺癌,在接受奥希替尼治疗期间有19个月无疾病进展。我们收集了一名肺腺癌患者的临床病理和家族数据。对先证者的肿瘤组织进行了40个关键基因的二代测序。为检测EGFR种系突变,对先证者及其两个女儿的外周血单个核细胞进行了桑格测序。在先证者的肺癌组织中发现了EGFR T790M、EGFR 19号外显子缺失、TP53和PIK3CA等突变。此外,通过对他们外周血样本的测序,在先证者及其女儿中证实了种系EGFR T790M突变。CT扫描显示两个女儿均有多个肺结节。

结论

这些观察结果表明,EGFR T790M种系突变可能与肺癌的家族易感性密切相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c9b9/11331667/4718ef935304/13053_2024_286_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c9b9/11331667/c0094e14623c/13053_2024_286_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c9b9/11331667/7d93e43ab431/13053_2024_286_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c9b9/11331667/a710070f1a0b/13053_2024_286_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c9b9/11331667/4718ef935304/13053_2024_286_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c9b9/11331667/c0094e14623c/13053_2024_286_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c9b9/11331667/7d93e43ab431/13053_2024_286_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c9b9/11331667/a710070f1a0b/13053_2024_286_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c9b9/11331667/4718ef935304/13053_2024_286_Fig4_HTML.jpg

相似文献

1
Benefits of osimertinib treat a lung adenocarcinoma patient with germline EGFR T790M, somatic EGFR 19-Del, TP53 and PIK3CA mutations.奥希替尼治疗一名具有胚系EGFR T790M、体细胞EGFR 19-缺失、TP53和PIK3CA突变的肺腺癌患者的益处。
Hered Cancer Clin Pract. 2024 Aug 19;22(1):13. doi: 10.1186/s13053-024-00286-4.
2
Significant Benefits of Osimertinib Against Adenosquamous Carcinoma Harboring Germline T790M Mutation.奥希替尼对携带胚系 T790M 突变的腺鳞癌的显著获益。
Oncologist. 2020 Oct;25(10):826-832. doi: 10.1634/theoncologist.2019-0938. Epub 2020 Jun 11.
3
The emergence of various genetic alterations mediated the Osimertinib resistance of a patient harboring heterozygous germline EGFR T790M: a case report.多种基因改变的出现介导了一名携带杂合性胚系EGFR T790M患者对奥希替尼的耐药性:一例报告。
Ann Transl Med. 2021 Jan;9(1):80. doi: 10.21037/atm-20-7626.
4
Mutational Profiling of Non-Small-Cell Lung Cancer Resistant to Osimertinib Using Next-Generation Sequencing in Chinese Patients.中国患者使用下一代测序技术对奥希替尼耐药的非小细胞肺癌进行突变分析。
Biomed Res Int. 2018 Mar 11;2018:9010353. doi: 10.1155/2018/9010353. eCollection 2018.
5
Afatinib overcoming resistance to icotinib and osimertinib in NSCLC with leptomeningeal metastasis in patients with acquired EGFR L858R/T790M or L858R/S768I mutations: Two case reports.阿法替尼克服携带获得性表皮生长因子受体(EGFR)L858R/T790M或L858R/S768I突变的非小细胞肺癌(NSCLC)伴软脑膜转移患者对埃克替尼和奥希替尼的耐药性:两例病例报告
Heliyon. 2023 Oct 8;9(10):e20690. doi: 10.1016/j.heliyon.2023.e20690. eCollection 2023 Oct.
6
Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre.在一家三级中心对已知表皮生长因子受体突变型非小细胞肺癌患者中各种代次的酪氨酸激酶抑制剂的原发性和获得性耐药的分子机制进行审计。
Clin Oncol (R Coll Radiol). 2022 Nov;34(11):e451-e462. doi: 10.1016/j.clon.2022.06.003. Epub 2022 Jul 7.
7
Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.基于皮升液滴数字聚合酶链反应的游离血浆DNA分析,以评估肺腺癌中对酪氨酸激酶抑制剂产生耐药性的表皮生长因子受体突变
Oncologist. 2016 Feb;21(2):156-64. doi: 10.1634/theoncologist.2015-0288. Epub 2016 Jan 14.
8
Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation.胰岛素样生长因子-1 受体的激活赋予 EGFR T790M 突变的非小细胞肺癌对奥希替尼的获得性耐药。
Thorac Cancer. 2020 Jan;11(1):140-149. doi: 10.1111/1759-7714.13255. Epub 2019 Nov 22.
9
Impact of the generation of EGFR-TKIs administered as prior therapy on the efficacy of osimertinib in patients with non-small cell lung cancer harboring EGFR T790M mutation.既往接受 EGFR-TKIs 治疗对携带 EGFR T790M 突变的非小细胞肺癌患者奥希替尼疗效的影响。
Thorac Cancer. 2021 Feb;12(3):329-338. doi: 10.1111/1759-7714.13742. Epub 2020 Nov 21.
10
Acquired EGFR L718V Mutation as the Mechanism for Osimertinib Resistance in a T790M-Negative Non-Small-Cell Lung Cancer Patient.奥希替尼耐药的非小细胞肺癌患者中 L718V 获得性 EGFR 突变作为机制。
Target Oncol. 2019 Aug;14(4):369-374. doi: 10.1007/s11523-019-00652-6.

本文引用的文献

1
Germline EGFR mutations in lung cancer (Review).肺癌中的种系表皮生长因子受体突变(综述)
Oncol Lett. 2023 May 16;26(1):282. doi: 10.3892/ol.2023.13868. eCollection 2023 Jul.
2
The emerging role of PI3K inhibitors for solid tumour treatment and beyond.PI3K 抑制剂在实体瘤治疗中的新兴作用及其他方面。
Br J Cancer. 2023 Jun;128(12):2150-2162. doi: 10.1038/s41416-023-02221-1. Epub 2023 Mar 13.
3
Overall survival in advanced epidermal growth factor receptor mutated non-small cell lung cancer using different tyrosine kinase inhibitors in The Netherlands: a retrospective, nationwide registry study.
荷兰使用不同酪氨酸激酶抑制剂治疗晚期表皮生长因子受体突变非小细胞肺癌的总生存期:一项回顾性全国登记研究
Lancet Reg Health Eur. 2023 Feb 6;27:100592. doi: 10.1016/j.lanepe.2023.100592. eCollection 2023 Apr.
4
A Primary Lung and Breast Cancer Patient with Germline R776H Mutation: A Case Report and Literature Review.一名携带胚系R776H突变的原发性肺癌和乳腺癌患者:病例报告及文献综述
Onco Targets Ther. 2023 Jan 18;16:17-22. doi: 10.2147/OTT.S391766. eCollection 2023.
5
Osimertinib showed efficacy on contralateral multiple ground-glass nodules after segmentectomy for lung adenocarcinoma harboring primary EGFR-T790M mutation: a case report and review of the literature.奥希替尼对原发性 EGFR-T790M 突变肺腺癌肺段切除术后对侧多发磨玻璃结节的疗效:病例报告及文献复习。
J Cardiothorac Surg. 2022 Dec 19;17(1):324. doi: 10.1186/s13019-022-02071-7.
6
Efficacy of osimertinib in a metastatic lung adenocarcinoma patient harboring somatic delL747_S752 and germline deletion polymorphism: a case report and literature review.奥希替尼在一名携带体细胞delL747_S752和种系缺失多态性的转移性肺腺癌患者中的疗效:病例报告及文献综述
Transl Cancer Res. 2022 Oct;11(10):3895-3902. doi: 10.21037/tcr-22-1050.
7
Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant Lung Adenocarcinoma.同时存在 TP53 突变促进 EGFR 突变型肺腺癌耐药进化。
J Thorac Oncol. 2022 Jun;17(6):779-792. doi: 10.1016/j.jtho.2022.02.011. Epub 2022 Mar 21.
8
First-line osimertinib treatment in a patient with lung adenocarcinoma with coexisting epidermal growth factor receptor G719S and de novo T790M mutations.奥希替尼一线治疗伴表皮生长因子受体 G719S 和新出现 T790M 突变的肺腺癌患者。
Thorac Cancer. 2022 Mar;13(5):771-774. doi: 10.1111/1759-7714.14288. Epub 2022 Jan 25.
9
Identification of the Unique Clinical and Genetic Features of Chinese Lung Cancer Patients With Germline Mutations in a Large-Scale Retrospective Study.一项大规模回顾性研究中中国携带胚系突变的肺癌患者独特临床及遗传特征的鉴定
Front Oncol. 2021 Nov 16;11:774156. doi: 10.3389/fonc.2021.774156. eCollection 2021.
10
Lung cancer is also a hereditary disease.肺癌也是一种遗传性疾病。
Eur Respir Rev. 2021 Oct 20;30(162). doi: 10.1183/16000617.0045-2021. Print 2021 Dec 31.